Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer

<table>(a) and (b) show exemplarily the regression of a lymph node metastasis, demonstrated by choline-PET-CT before and 10 months after treatment with trofosfamide.</table>

Case Reports in Medicine

fig2

Figure 2

Figure 2: Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer 

Figure 2 | Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer 